| Automated sample preparation with SP 3 for low‐input clinical proteomics T Müller, M Kalxdorf, R Longuespée, DN Kazdal, A Stenzinger, ... Molecular systems biology 16 (1), e9111, 2020 | 161 | 2020 |
| Optimizing panel-based tumor mutational burden (TMB) measurement J Budczies, M Allgäuer, K Litchfield, E Rempel, P Christopoulos, D Kazdal, ... Annals of Oncology 30 (9), 1496-1506, 2019 | 137 | 2019 |
| Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study A Stenzinger, V Endris, J Budczies, S Merkelbach-Bruse, D Kazdal, ... Journal of Thoracic Oncology 15 (7), 1177-1189, 2020 | 97 | 2020 |
| Variant classification in precision oncology J Leichsenring, P Horak, S Kreutzfeldt, C Heining, P Christopoulos, ... International journal of cancer 145 (11), 2996-3010, 2019 | 95 | 2019 |
| Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts D Kazdal, V Endris, M Allgäuer, M Kriegsmann, J Leichsenring, ... Journal of Thoracic Oncology 14 (11), 1935-1947, 2019 | 86 | 2019 |
| Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair–associated genes C Kratochwil, FL Giesel, CP Heussel, D Kazdal, V Endris, C Nientiedt, ... Journal of Nuclear Medicine 61 (5), 683-688, 2020 | 72 | 2020 |
| Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays N Pfarr, M Kirchner, U Lehmann, J Leichsenring, S Merkelbach‐Bruse, ... Genes, Chromosomes and Cancer 59 (3), 178-188, 2020 | 60 | 2020 |
| Artificial intelligence and pathology: from principles to practice and future applications in histomorphology and molecular profiling A Stenzinger, M Alber, M Allgäuer, P Jurmeister, M Bockmayr, J Budczies, ... Seminars in cancer biology 84, 129-143, 2022 | 59 | 2022 |
| Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56 K Kriegsmann, C Zgorzelski, D Kazdal, M Cremer, T Muley, H Winter, ... Applied Immunohistochemistry & Molecular Morphology 28 (3), 237-242, 2020 | 48 | 2020 |
| MALDI imaging‐guided microproteomic analyses of heterogeneous breast tumors—a pilot study D Alberts, C Pottier, N Smargiasso, D Baiwir, G Mazzucchelli, P Delvenne, ... PROTEOMICS–Clinical Applications 12 (1), 1700062, 2018 | 45 | 2018 |
| A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma J Budczies, M Kirchner, K Kluck, D Kazdal, J Glade, M Allgäuer, ... Oncoimmunology 10 (1), 1860586, 2021 | 44 | 2021 |
| RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples M Kirchner, O Neumann, AL Volckmar, F Stögbauer, M Allgäuer, D Kazdal, ... Cancers 11 (9), 1309, 2019 | 44 | 2019 |
| Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications D Kazdal, V Hofman, P Christopoulos, M Ilié, A Stenzinger, P Hofman Genes, Chromosomes and Cancer 61 (5), 244-260, 2022 | 42 | 2022 |
| Copy number changes of clinically actionable genes in melanoma, non‐small cell lung cancer and colorectal cancer—A survey across 822 routine diagnostic cases N Pfarr, R Penzel, F Klauschen, D Heim, R Brandt, D Kazdal, ... Genes, Chromosomes and Cancer 55 (11), 821-833, 2016 | 41 | 2016 |
| Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer L Daniello, M Elshiaty, F Bozorgmehr, J Kuon, D Kazdal, H Schindler, ... Frontiers in Oncology 11, 703893, 2021 | 39 | 2021 |
| Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA S Dietz, P Christopoulos, Z Yuan, AK Angeles, L Gu, AL Volckmar, ... EBioMedicine 62, 2020 | 36 | 2020 |
| Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer K Kriegsmann, M Cremer, C Zgorzelski, A Harms, T Muley, H Winter, ... Pathology 51 (3), 240-245, 2019 | 35 | 2019 |
| YAP orchestrates heterotypic endothelial cell communication via HGF/c-MET signaling in liver tumorigenesis S Thomann, SME Weiler, S Marquard, F Rose, CR Ball, M Tóth, T Wei, ... Cancer Research 80 (24), 5502-5514, 2020 | 34 | 2020 |
| Deciphering the immunosuppressive tumor microenvironment in ALK-and EGFR-positive lung adenocarcinoma J Budczies, M Kirchner, K Kluck, D Kazdal, J Glade, M Allgäuer, ... Cancer Immunology, Immunotherapy 71 (2), 251-265, 2022 | 33 | 2022 |
| NTRK testing: First results of the QuiP‐EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA‐based … M Kirchner, J Glade, U Lehmann, S Merkelbach‐Bruse, M Hummel, ... Genes, Chromosomes and Cancer 59 (8), 445-453, 2020 | 33 | 2020 |
Albrecht Stenzinger, MDInstitute of Pathology, University Hospital Heidelberg, GermanyVerified email at med.uni-heidelberg.de
